Article
Allergan to Acquire KYTHERA Biopharmaceuticals
Allergan and KYTHERA Biopharmaceuticals today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity transaction.
PRESS RELEASE
DUBLIN
and
WESTLAKE VILLAGE, Calif.
,
June 17, 2015
/PRNewswire/ --
Allergan plc
(NYSE: AGN), a leading global pharmaceutical company, and
KYTHERA Biopharmaceuticals, Inc.
(NASDAQ: KYTH), a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that they have entered into a definitive agreement under which
Allergan
has agreed to acquire KYTHERA in a cash and equity transaction valued at
$75
per KYTHERA share, or approximately
$2.1 billion
, subject to the fulfillment of certain customary conditions summarized below. The fixed-value transaction consideration will be payable 80 percent in cash and 20 percent in new AGN shares issued to KYTHERA shareholders.
Allergan's
2015 earnings-per-share forecast provided on
May 11, 2015
is unchanged as a result of the acquisition. The acquisition is expected to be breakeven in 2016 and accretive thereafter. The Company remains committed to de-levering to below 3.5x debt to Adjusted EBITDA by the end of the first quarter of 2016.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
